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Abstract: Background and objectives: The use of antibiotic prophylaxis in extraction and implant
dentistry is still controversial, with varying opinions regarding their necessity. The overuse of
antibiotics has led to widespread antimicrobial resistance and the emergence of multi drug resistant
strains of bacteria. The main aim of this work was to determine whether there is a genuine need
for antibiotic prophylaxis in two common dental procedures; dental implants and tooth extractions.
Methods: Electronic searches were conducted across databases such as Cochrane Register of Controlled
Trials, the UK National Health Service, Centre for reviews, Science Direct, PubMed and the British
Dental Journal to identify clinical trials of either dental implants or tooth extractions, whereby the
independent variable was systemic prophylactic antibiotics used as part of treatment in order to
prevent postoperative complications such as implant failure or infection. Primary outcomes of interest
were implant failure, and postoperative infections which include systemic bacteraemia and localised
infections. The secondary outcome of interest was adverse events due to antibiotics. The Critical
Appraisal Skills Programme tool was used to assess the risk of bias, extract outcomes of interest and
to identify studies for inclusion in the meta-analysis. Results: Seven randomised clinical trials (RCTs)
were included in the final review comprising n = 1368 patients requiring either tooth extraction(s)
or dental implant(s). No statistically significant evidence was found to support the routine use of
prophylactic antibiotics in reducing the risk of implant failure (p = 0.09, RR 0.43; 95% CI 0.16–1.14)
or post-operative complications (p = 0.47, RR: 0.74; 95% CI 0.34–1.65) under normal conditions.
Approximately 33 patients undergoing dental implant surgery need to receive antibiotics in order to
prevent one implant failure from occurring. Conclusions: There is little conclusive evidence to suggest
the routine use of antibiotic prophylaxis for third molar extractive surgery in healthy young adults.
There was no statistical evidence for adverse events experienced for antibiotics vs. placebo. Based on
our analysis, even if financially feasible, clinicians must carefully consider the appropriate use of
antibiotics in dental implants and extraction procedures due to the risk of allergic reactions and the
development of microbial drug resistance.
Keywords: antibiotic prophylaxis; microbial drug resistance; dental extraction; dental implants
1. Introduction
Since the accidental discovery of antibiotics by Sir Alexander Fleming of Scotland in 1929,
they have been the greatest contribution to the 20th century world of therapeutics [1]. Initially
the first systemic antibiotics (penicillin and sulphonamides) were reserved only for military use during
World War II due to the expense and complicated manufacturing processes. As these processes were
simplified, new formulations were developed, access to antibiotics increased and widespread use
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began [2]. Thereafter was a significant reduction in morbidity and mortality that were associated with
previously life threatening diseases such as scarlet fever, pneumonia, meningitis and diphtheria [3].
1.1. Antimicrobial Prescribing Trends in Dentistry
Dental extractions are commonly performed by dentists for a wide variety of reasons including
dental caries, impacted teeth, orthodontic and periodontal treatment and trauma [4]. A dental implant
is a surgical component used to replace missing teeth [5] which interfaces with the skull or jaw bone
in order to support a dental prosthesis such as a crown. Bacterial contamination during implant
placement is thought to be responsible for early implant losses and infected dental implants are
difficult to treat, and 2% eventually will be removed [6]. Antibiotics are not simply alternatives to
dental interventions, but act as an adjunct to treatment. They may indicate when clinical signs of
involvement are evident. Prophylactic antibiotic treatment is the use of antibiotics before, during or
after therapeutic, diagnostic or surgical procedures with the aim of preventing infectious complications.
This differs to therapeutic antibiotic treatment which aims to clear infection caused by a colonising
micro-organism [7]. A common practice among dentists worldwide is prescribing prophylactic
antimicrobials for procedures causing bleeding in the oral cavity [8]. The use of prophylactic antibiotics
in dental implants and extractions is highly controversial, with varying opinions regarding their
necessity [8–11].
Dentists prescribe approximately 10% of all common antibiotics [12]. In dentistry, the use
and indications for systemic antibiotics are limited as most dental and periodontal diseases are
usually best managed by operative interventions and oral hygiene measures [13,14]. According to the
National Centre for Disease Control and Prevention, approximately one in three outpatient antibiotic
prescriptions are deemed unnecessary [14].
Prophylactic treatment is often decided on the presumption of an infection happening, for example,
Staphylococci, Streptococci and anaerobic rods are the most common causes of wound infection in oral
surgery [15] and as a result, broad spectrum antibiotics are typically prescribed, amoxicillin being
the most common choice of clinicians [16,17]. Interestingly, a study conducted by Anderson et al.
(2000) concludes that General Practioners (GPs) are more likely to prescribe antibiotics, specifically
broad-spectrum, for acute dental problems in comparison to dentists. Table 1 provides a summary of
the most commonly prescribed antibiotics used in current dentistry [18].
Studies investigating prophylactic antibiotic prescribing carried out in developed countries
indicate that dentists have better clinical knowledge of antibiotic prescribing [17] compared to
studies conducted in developing countries which reported the misuse of prophylactic antibiotic
prescribing [17–20]. In 2010 India, China and United States of America were the top global consumers
of antibiotics.
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Table 1. Summary of commonly prescribed antimicrobial drugs in dentistry in the UK. Adapted from Ramu & Padmanabhan (2012) and the British National
Formulary (BNF, 2013) [21,22].
Antibiotic Class Drug Mechanism Spectrum of Activity Common Indicationsin Dentistry Dose Range Comments
Amoxicillin Penicillin Inhibits biosynthesisof cell wall
Broad spectrum.
Active against certain
gram + and gram −
organisms
Dentoavleolar abscess
250 mg three times
daily (dose can be
doubled in severe
infections)
Just as effective as
phenoxymethyl penicillin but
better absorbed. Ineffective
to beta lactamase producing
organisms.
Ampicillin Penicillin Inhibits biosynthesisof cell wall
Broad spectrum.
Active against certain
gram + and gram −
organisms
Dentoavleolar abscess 500–1000 mg fourtimes daily See amoxicillin
Penicillin V
Phenoxymethylpenicillin Penicillin
Inhibits biosynthesis
of cell wall
More active against
gram + than gram -
Dentoavleolar abscess.
Should not be used in
serious infections.
500 mg four times
daily (dose can be
doubled in severe
infections)
Gastric acid-stable therefore
suitable for oral
administration unlike
penicillin G
Co-Amoxiclav Penicillin Inhibits biosynthesisof cell wall
Broad spectrum.
Active against
beta-lactamase
producing bacteria
resistant to
amoxicillin
Severe dental
infection with
spreading cellulitis or
dental infection
non-responsive to 1st
line antibacterial.
250 mg/125 mg
(ampicillin/clauvic
acid) combination
tablet three times
daily (higher dose of
500 mg/125 mg in
severe infections)
A mixture of clauvulanic acid
acting as beta-lacamase
inhibitor (as potassium
clavulanate) and amoxicillin
(as trihydrate/sodium salt)
Cefalexin Cephalosporin
Binds to penicillin
binding proteins and
inhibits cell
wall synthesis.
More active
against aerobes
Dental infections
resistant to
penicillin VK
250–1500 mg four
times daily
Offer little advantage over
penicillin’s in dental
infections but useful in those
with hypersensitivity to
penicillin’s
Cefradine Cephalosporin
Binds to penicillin
binding proteins and
inhibits cell
wall synthesis.
More active
against aerobes
Dental infections
resistant to
penicillin VK
250–1000 mg four
times daily See Cephalexin
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Table 1. Cont.
Antibiotic Class Drug Mechanism Spectrum of Activity Common Indicationsin Dentistry Dose Range Comments
Metronidazole Metronidazole Inhibiting nucleicacid synthesis
High activity against
anaerobic bacteria
and protozoa
Acute necrotising
gingivitis,
pericoronitis
200–250 mg three
times daily
High concentration builds up
achievable in tissue.
Clarithromycin Macrolide Inhibits bacterialpeptide translation
Similar but not
identical to penicillin
2nd line drug
treatment for dental
abscess
250–500 mg twice
daily
Many organisms rapidly
develop resistance to
macrolides; use should be
limited to short courses
Doxycycline Tetracycline Inhibits bacterialprotein synthesis
Effective against oral
anaerobes. Sinusitis
200 mg initially, 100
mg daily
Due to antibiotic resistance,
especially by oral
streptococci, tetracycline
usefulness is reduced in
acute oral infections.
* Local formulary dose recommendation may differ to BNF doses.
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1.2. Antibiotic Resistance
According to the World Health Organisation (WHO), antibiotics are the most misused of
all medicines due to ease of access, being inexpensive, familiar and with generally good safety
profiles. This has led to the growing problem of antimicrobial resistance (AMR) which is becoming a
global threat that could cause an eventual loss of antibiotic efficacy [23]. The Global Antimicrobial
surveillance (GLASS) programme runs by WHO revealed 500,000 people across 22 countries with
suspected infections becoming antibiotic resistant with microorganisms such as Escherichia coli, Klebsiella
pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, and Salmonella spp. showing high rates
of antibiotic resistance [24]. The European Union (EU) fact sheet on AMR estimates that antibiotic
resistance results in approximately 25,000 deaths per year and in excess of €1.5 billion in related
healthcare costs and productivity losses leading to resistance against different classes of antibiotics
discovered to date [3,25]. Alanis (2005) reports that infections caused by the new strains of antibiotic
resistant bacteria are not only difficult to treat but require longer courses of antibiotics and more
complex therapy [2].
The new EU ‘One health action plan against AMR’ primarily aims to reduce the emergence and
spread of AMR, thereby preserving the efficacy of existing antimicrobial agents for use in both humans
and animals. In addition, greater monitoring and surveillance, strengthening infection prevention
and control measures, promoting the appropriate use of antimicrobial agents followed by developing
new alternative treatments and increasing awareness and understanding of AMR among both public
and healthcare professionals were advocated by the EU action plan [26]. WHO has published a global
strategy for the containment of resistance. The guidelines identified 68 recommendations calling for
governments and health systems to produce their local guidelines [25,27].
1.3. Clinical Guidelines
Infective endocarditis (IE) is a severe infection causing inflammation of the endocardium due to a
range of infectious agents including Staphylococci, Streptococci, fungi and Pseudomonas aerunginosa [28]
and has a high mortality rate. Since many dental procedures cause bacteraemia, this may lead
to invasive endocarditis in susceptible individuals. Previously, various national and international
guidelines recommended that prior to invasive orthodontic procedures; those individuals at heightened
risk of developing IE should be administered prophylactic antibiotics [17]. In general, prophylactic
antibiotics are only recommended in surgery for:
• Patients at risk of infectious endocarditis (except in non-surgical dental procedures)
• Immuno-compromised patients
• For prolonged and extensive surgical interventions
• Surgery in infected sites
• When large foreign materials are implanted
In 2008 the National Institute for Health and Clinical Excellence (NICE) published clinical
guidelines [29–31] on antibiotic prophylaxis against infective endocarditis (IE), recommending that
antibiotics for the purpose of preventing the development of IE should not be given to adults and
children at risk of IE who are undergoing dental procedures. Prior to this, preventative antimicrobials
were prescribed for prevention of IE for many decades. The evidence for this decision was that a
consistent association between a patient having an interventional procedure and the risk of developing
IE could not be found [28]. Therefore, it is on this basis that the clinical effectiveness of prophylactic
antimicrobials is not considered to be proven [31–33]. These guidelines further suggest prophylactic
antibiotics used against IE for dental procedures are not cost effective [29,30]. According to NICE
regular tooth brushing almost certainly presents a greater risk of IE than a single dental procedure
because of repetitive exposure to bacteraemia with oral flora [29].
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Antibiotics are however appropriate for oral infections where there is evidence of spreading
infection (swelling, lymph node involvement and cellulitis) or systemic involvement such as malaise
and fever according to the Scottish Dental Clinical Effectiveness Programme [13].
The National Health Service (NHS) dentists are required to observe the guidance of NICE whilst
prescribing. Clinicians who work privately may not have the same contractual obligation to follow
this guidance. They would however require strong justification to their local clinical commissioning
groups (CCGs) for choosing not to do so [30].
Implementing a change in clinical practice has own set of problems, even if the proposed changes
are evidence based via national guidelines, because it not only involves studying new evidence but
also abandoning the old evidence [31]. Cottingham (2012) reports that much needs to be done in order
to improve the understanding of NICE guidelines among the dental profession as only 62% of dental
trainers and 69.7% of dental trainees have read the CG No. 64 guideline and 55.7% trainers and 77.6%
trainees applied it [32].
1.4. Study Aim
The study aim was designed using Process, Intervention, Comparator and Outcomes (PICO)
guidelines. The purpose of this systematic review was to determine whether there is a genuine need
for antibiotic prophylaxis in two common dental procedures; dental implants and tooth extractions,
for which antibiotics are still currently being prescribed as part of therapy.
2. Methods
2.1. Search Strategy
Initial electronic searches were conducted using the Cochrane Register of Controlled Trials,
the UK National Health Service (NHS) Centre for reviews, Science Direct, PubMed and the British
Dental Journal to identify clinical trials of either dental implants or tooth extractions, whereby the
independent variable was systemic prophylactic antibiotics used as part of treatment in order to
prevent postoperative complications (implant failure, infection).
The following search terms were used in various combinations in all specified databases:
‘dentistry’, ‘prophylactic antibiotics’, ‘antibiotic prophylaxis’, ‘infection’, ‘extraction’, ‘third molar’,
‘bacteraemia’, ‘implant’, ‘antimicrobial’. Primary outcomes of interest were implant failure,
postoperative infections (including systemic), bacteraemia localised infections and other post-surgical
related complications of infectious nature (fever, swelling, trismus, pain, purulent discharge, alveolar
osteitis. Secondary outcomes of interest were any adverse events due to antibiotics).
2.2. Study Criteria
The study was designed based on the PRISMA guidelines to produce systematic review and
perform metanalysis. Potential studies identified in the initial search were required to meet inclusion
criteria; clinical randomised control trials investigating dental implant or tooth extraction for any
indication using prophylactic antibiotics as part of treatment to prevent postoperative complications
such as implant failure or infection. Clinical trials were also required to be published in English and
from 2000 until 2013. Studies which did not contain a control group and were not randomised were
also excluded from this review (Table 2). A double-blind RCT is of significant importance to eliminate
the Hawthorn effect where patients may report fewer or more adverse events depending on personal
beliefs or interpretation of the medication used [33].
2.3. Quality Assessment and Risk of Bias
Each study was critically appraised using the critical appraisal skills programme (CASP) tool
checklist for clinical trials. To assess for risk of bias the RCTs were checked against four main quality
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criteria by the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 (study details for each criterion can be found in Appendices A and B):
1. Patient blinding
2. Assessor blinding
3. Allocation concealment
4. Participant compliance with follow-up
3. Results
A total of 1469 articles were identified by the electronic searches conducted on the specified
databases. Titles and abstracts were analysed for relevancy to this work resulting in 1434 articles being
irrelevant and subsequently rejected. Thirty-five full text articles were reviewed, however 14 were
irretrievable and 8 had a lack of compliance with inclusion criteria or inappropriate interventions
and therefore rejected. Thirteen full text articles then underwent detailed analysis resulting in 6
further studies being excluded from this review. Seven randomised clinical trials (RCTs) were included
in the final review comprising of a total of 1368 patients (657 extraction patients and 711 implant
patients) requiring either tooth extraction(s) or dental implant(s). All included studies were published
in English and complied with the inclusion criteria. All of these studies compared at least one type of
antibiotic regimen against placebo in patients undergoing either dental extraction or implant placement
(Figure 1).
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Each of the randomised clinical trials used in this review were then categorised according to the
level of bias as determined by the above specified criteria (Tables 2 and 3).
Table 2. Rationale for each level of bias.
Level of Bias Description
High risk Possible bias seriously affecting the reliability of the results and highrisk of bias if one or more of the criteria were not met
Low risk Possible bias not seriously affecting the reliability of the results andlow risk of bias if all criterion met
Table 3. Risk of bias for studies based on 4 main criteria recommend by Cochrane Handbook for
systematic reviews of interventions Version 5.1.0.
Study PatientBlinding
Assessor
Blinding
Allocation
Concealment Withdrawals Risk of Bias
Anitua et al. (2009) Yes Yes Concealed None Low
Caiazzo et al. (2011) Yes Yes Unclear None High
Esposito et al. (2010) Yes Yes Concealed Yes (enough reasonshave been provided) Low
Sekhar et al. (2001) Yes Yes Concealed Yes High
Dios et al. (2006) Yes Yes Concealed None Low
Kaczmarzyk et al. (2007) Yes Yes Concealed Yes High
Lacasa et al. (2007) Yes Yes Unclear risk None Low
Sekhar et al. (2001) was the only extraction study where multiple extractions per patient were
allowed [12]. All participants were ≥18 years of age with various form of edentulism, however only
one clinical implants study [34] included patients that required a single implant supported crown.
The greatest difference in ratio of males to females in any arm of any study was seen in the Kaczmarzyk
et al. (2007) placebo group [35]. Implant studies have a greater mean age than extraction studies. No
study included elderly, young children or immune compromised patients (Table 4).
Table 4. A summary of study population characteristics.
Study
(Author)
Extraction/
Implant Intervention
Number of
Participants
Gender
(m/f)
Mean Age
(Years)
Number of
Extractions/Implants
Caiazzo et al. Implant Amoxicillin 2 g 1 h pre-op 25 13/12 52 35
Amoxicillin 2 g 1 h pre-op
+ amoxicillin 2 g daily for
7 days post-op
25 12/13 45 36
Amoxicillin 2 g daily
post-op for 7 days 25 7/18 42 48
No antibiotic 25 10/15 43 29
Anitua et al. Implant Amoxicillin 2 g 1 h pre-op 52 15/37 49 52
Placebo (identical
tablests) 2 g 1 h pre-op 53 20/33 47 53
Esposito et al. Implant Amoxicillin 2 g 1 h pre-op 252 114/138 49.1 489
Placebo (no antibiotic) 254 122/132 47.6 483
Sekhar et al. Extraction Metronidazole 1 g orally 1h preoperatively 44 25/19 28 99
Metronidazole 400 mg
orally 4 times daily for 5
days
47 30/17 29 101
placebo 34 15/19 26 103
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Table 4. Cont.
Study
(Author)
Extraction/
Implant Intervention
Number of
Participants
Gender
(m/f)
Mean Age
(Years)
Number of
Extractions/Implants
Dios et al. Extraction Amoxicillin 2 gpreoperatively 56 34/22 23.8 56
moxifloxacin 400 mg
preoperatively 58 29/29 22.4 58
clindamycin 600 mg
preoperatively 54 34/20 24 54
Placebo 53 29/24 26.1 53
Kaczmarzyk et
al. Extraction
Clindamycin 600 mg
preoperatively then 300
mg placebo for 5 days
31 8/23 23.4 31
Clindamycin 600 mg
preoperatively then 300
mg placebo for 5 days
post-op
28 9/19 23.5 28
placebo 27 6/21 24.6 27
Lacasa et al. Extraction
Pre-op
amoxicillin/clavulanate
2000/125 mg
75 33/42 29.7 75
post-op
amoxicillin/clavulanate
2000/125 mg
75 37/38 29.5 75
placebo 75 26/49 28.2 75
3.1. Extraction Studies
Four of the seven studies involved prophylactic antibiotics for dental extraction. All four extraction
studies were multi-arm randomised control trials comprising of a total of 657 patients requiring
single/multiple dental extractions (835 extractions) for various indications (impacted wisdom teeth,
abscess etc). Three studies were conducted in Europe [34–36], whilst the fourth was conducted in
India [12]. All extraction studies involved patients being treated at referral centres by oral surgery
specialists rather than general dental practitioners. All extractions studies used local anaesthesia to
perform dental extractions and each study contained compared at least one antibiotic regimen against
placebo. Interestingly, the most common indications for dental extraction are caries or periodontal
disease, yet no trials were identified which assessed the effect of prophylactic antibiotics in patients
requiring dental extraction for these indications (Table 4).
3.1.1. Dios et al. (2006) Trial
The authors performed microbiological analysis on post-operative bacteraemia present in blood
cultures as an outcome measure to determine the effectiveness of prophylactic antibiotics in dental
extraction. Dios et al. (2006) found Streptococcus spp. were the most commonly identified bacteria in
all groups ranging from 44% to 68% with the lowest percentage being detected from the amoxicillin
group (p < 0.0001). Amoxicillin and moxifloxacin prophylaxis showed high efficacies (p < 0.001 and
p < 0.05 respectively) in reducing prevalence and duration of bacteraemia following dental extraction.
Clindamycin prophylaxis was seen to be non-effective (p < 0.9). The results of the study therefore
implicate that amoxicillin and moxifloxacin would be highly likely to reduce post-operate infections
following dental extraction [36].
3.1.2. Lacasa et al. (2007) Trial
The authors conducted a phase III comparative study evaluating the efficacy of two schedules of
a sustained release amoxicillin/clavulanate preparation in order to reduce infection after third molar
surgery. A total of 225 patients were randomised equally into three groups: placebo, prophylaxis
using single pre-op dose of amoxicillin/clavulanate 2000/125 mg, and a pre-emptive therapy group
given a matching placebo dose (2000/125 mg) pre-op followed by amoxicillin /clavulanate 2000/125
mg twice daily for 5 days. A statistically significant higher rate of infection was seen amongst the
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placebo group: 16% (12/75) vs. single dose prophylaxis: 5.3% (4/75) vs. 5-day pre-emptive therapy:
2.7% (2/72) (p = 0.006). A linear correlation was found between the length of procedure and rate
of incidence (p < 0.027) probably due to the length of exposure associated with more lengthy and
complex bone removal procedures (ostectomy). Both therapeutic and prophylactic regimes vs. placebo
had achieved greater reduction of pain postoperatively (p = 0.0001). However, prophylaxis was seen
to be more beneficial in cases where ostectomy is not performed [34]. Overall results favoured the
use of pre-emptive antibiotic therapy to reduce the rate of subsequent infection in patients subjected
to ostectomy and a single prophylactic dose to be useful in simpler extraction procedures. Out of 8
planned outcomes that were listed, only one was explained fully whilst pain was reported as a mean
for each arm of the trial without estimate variance [37].
3.1.3. Kaczmarzyk et al. (2007) Trial
This study involved 86 patients to evaluate the efficacy of a single and multi-dose clindamycin
5-day therapy to prevent inflammatory complications after third molar extractive surgery requiring
bone removal. Clindamycin was chosen as it exerts strong antimicrobial action towards isolated
strains from odontic infections as well as reaching high tissue concentrations. The only statistically
significant result for any of the outcome measures (trismus, facial swelling, body temperature, pain,
alveolar osteitis and lymphadenopathy) was a variation in body temperature was reported on the
7th day post-op (p = 0.03, Kruskal–Wallis rank test). All other outcome measure results in the
study were p > 0.05, indicating a lack of statistical significance regarding efficacy in prophylaxis
and pre-emptive therapy in any examined group. Results do not support the use of prophylactic
antibiotics using clindamycin for preventing inflammatory complications in those requiring third
molar extraction with bone removal under normal conditions [35].
3.1.4. Sekhar et al. (2001) Trial
Sekhar et al. (2001) (high risk of bias) tested the efficacy of two dosing regimens of prophylactic
antibiotics during removal of impacted lower third molars using 151 participants (Table 5). They used
random allocation into three groups: placebo vs. prophylactic antibiotics pre-op vs. antibiotic treatment
post-op for 5 days. Metronidazole was the antibiotic of choice but was not justified. Pain score, swelling
and wound state were all assessed on day 2 and 6 postoperatively. Results showed no significant
differences in the outcome between the three groups (p = 0.09). Between individual variables assessed
(swelling, pain, wound discharge), the degree of swelling was significantly less in the 5-day antibiotic
post-op group (p = 0.03). The study concludes that in this case, results failed to show advantage in any
group. Prophylactic antibiotics did not reduce morbidity after the removal of impact third molars [12].
Medicina 2018, 54, 95 11 of 27
Table 5. A summary of key characteristics for randomised clinical extraction studies evaluating the effectiveness of antibiotics in preventing
post-operative complications.
Study
(Author)
Complication/
Procedure Intervention
Patient Sample
Size Study Design Outcomes Assessed Location Results Comments
Sekhar et al. (2001) Lower wisdomtooth extraction
Metronidazole 1 g
orally 1h preoperatively
vs. metronidazole 400
mg orally 4 times daily
for 5 days vs placebo
n = 151
3-arm,
randomised,
double blind
Purulent discharge
from wound, dry
socket, swelling, pain
score
India
Overall, no significant
differences in groups
from any of the
variables.
Outcome assessment
procedures were not clearly
specified. No power
analysis performed. At
enrolment patients’ key
characteristics not fully
assessed.
Kaczmarzyk et al.
(2007)
Extraction of
third molar
tooth.
Clindamycin 600 mg
preoperatively then 300
mg placebo vs.
Clindamycin 600 mg
preoperatively then 300
mg placebo post-op vs.
placebo (5 day
treatment)
n = 86
3-arm
prospective,
randomised,
double blind
Using 4-grade scale:
Trismus, facial swelling,
pain, body temperature
& alveolar osteitis. All
evaluated on day 1, 2
and 7 (post-op)
Poland
No statistically
significant differences
in post-op complication
rates for third molar
extraction from any
group.
Incomplete outcome data
(attrition bias)—14%
patients lost at follow up.
Inclusion criteria basic.
Exclusion criteria well
described. Power analysis
performed. Demographic,
objective and subjective
data clearly defined.
Dios et al. (2006)
Tooth extraction
for any
indication
Amoxicillin 2 g
preoperatively vs.
moxifloxacin 400 mg vs.
clindamycin 600mg
(preoperatively vs.
placebo
(5 day treatment)
n = 221
3-arm,
randomised,
double blind
Postoperative
bacteraemia levels
determined by
microbiological
analysis of blood
cultures.
Spain
Postoperative
measurements of
bacteraemia showed
decrease in amoxicillin
and moxifloxacin
(p < 0.0001) vs. placebo
Clear exclusion criteria
described, however unclear
description of inclusion
criteria. Power analysis
performed.
Lacasa et al. (2006)
Third
mandibular
surgery
required
Pre-op
amoxicillin/clavulanate
2000/125 mg vs.
post-op
amoxicillin/clavulanate
2000/125 mg vs.
placebo
(5 day treatment)
n = 225
3-arm
randomised,
double blind,
parallel, phase
III comparative
study
Infection (purulent
discharge in surgical
site, pain, local abscess,
increased heat, pyrexia,
trismus, dental osteitis.
All evaluated on days
1,3,7 post-op.
Spain
Higher rate of infection
was seen in placebo
group (16%) vs. single
dose prophylaxis (5.3%)
vs. 5 day pre-emptive
therapy (2.7%)
(p = 0.006)
Patients lost at each follow
up not mentioned.
Incomplete outcome data
(attrition bias).
Randomisation method not
clearly defined. Two
authors are employed by
the funding company.
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3.2. Dental Implant Studies
Three implant studies were included in the final review comprising of 711 patients (1225 implants).
All three implant studies were randomised and double-blinded. Two studies were multicentre parallel
studies [6,15] conducted in Italy whilst the third study [31] was conducted in Spain. All three
multicentre trials were conducted in private dental practices. Only one trial was supported by the
implant manufacturer [31,34]. One clinical study [6] used placebo and antibiotics which were donated
from a generic drug manufacturing company (Table 6).
3.2.1. Esposito et al. (2010)
Esposito et al. (2010) (low risk of bias) compared 2 g amoxicillin 1 h preoperatively with identical
placebo tablets using 506 patients. Outcome measures of interest were prosthesis/implant failure,
postoperative complications and adverse events. Ten participants experienced prosthesis failure in
the placebo group in comparison vs. 4 in the antibiotic group. Severn implant failures occurred in
the antibiotic group vs. 13 in the placebo group. The difference at patient level was not statistically
significant (p = 0.083). The placebo group had twice the rate of infection vs. the antibiotic group (n = 8
vs. n = 4 respectively). Immediate post-extractive implants were more likely to fail in comparison to
delayed implants (9% vs. 2% respectively). Although trends clearly favoured the antibiotic group,
no statistically significant differences were observed for outcome measures and no adverse events
were reported. The authors conclude that sample size was insufficient to show a statistically significant
difference [6].
3.2.2. Anitua et al. (2009)
Anitua et al. (2009) (low risk of bias) compared 2 g of amoxicillin 1 h preoperatively with identical
placebo tablets when placing single implants in bone types II & III. The characteristics of saprophytic
flora were also examined in all patients. A total of 105 patients were recruited (52 in antibiotic group
and 53 in placebo group). The duration of follow up was 3 months after placement. In each group two
participant experienced implant failures and 6 experienced postoperative infections. No statistically
significant differences were found between groups for post-operative infection (p = 0.960). The authors
found that the use of amoxicillin did not modify the natural saprophytic flora (p = 0.362). No adverse
events were reported [34].
Overall, trends favour the use of antibiotics in implant, but results are not statistically significant
in order to support the use of prophylactic antibiotics in single implant placement for any of the
outcome measures.
3.2.3. Caiazzo et al. (2011)
This study (high risk of bias) compared 4 interventions (n = 25 for each group): single dose 2 g
amoxicillin 1-h pre-op vs. 2 g amoxicillin 1-h pre-op + 1 g twice daily for 7 days vs. 1 g amoxicillin
post-op twice daily for 7 days vs. no antibiotic. The duration of follow up was 3 months after placement.
No patients dropped out at any time. Two implant failures occurred in the placebo group vs. no
failures in any of the 3 antibiotic groups (n = 75 patients). No statistically significant differences were
observed for between groups (p > 0.05). No postoperative complications were reported in any group
at weeks 1, 2, 4 and 8. No adverse events had been reported. Overall the authors concluded the lack of
statistically significant evidence was perhaps due to the limited number of samples but still believe that
implant placement may be one of the limited oral surgical procedures requiring routine antimicrobial
prophylaxis [15].
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Table 6. A summary of key characteristics for randomised clinical implant studies evaluating the effectiveness of antibiotics in preventing implant failure.
Study
(Author)
Complication/
Procedure Intervention Sample Size Study Design Outcomes Assessed Location Results Comments
Caiazzo et al. (2010) Dental implantsurgery
Amoxicillin 2 g pre-op
vs. Amoxicillin 2 g
daily pre & post-op
(7days) vs. amoxicillin
2 g post-op (7days) vs.
placebo
n = 100
4-arm,
prospective,
multicentre
parallel,
randomised,
study
(3 month study)
Implant failure,
postoperative
complications assessed
post-op at weeks 1,2,4
and 8, adverse events
Italy
Overall success rate 98.65%.
No significant differences
between expt. groups (p <
0.05). no implant failures in
antibiotic groups, 2 failures
in non-antibiotics groups.
Allocation concealment
information not
provided.
No information
provided for blinding
of operators.
Esposito et al.
(2010)
Dental implant
surgery
Amoxicillin 2g pre-op
vs. placebo n = 506
Randomised,
multicentre,
double blind,
placebo
controlled &
parallel (4
month duration)
Implant & prosthesis
failure. Post-op
complications (assessed
weeks 1 & 2 post-op),
and adverse events.
Italy
No statistically significant
differences observed
between groups but trend
favoured antibiotic
administration. More
implant losses in placebo
group
(p = 0.083)
Limitations of the study
well described.
Allocation concealment
information well
provided. Information
provided for blinding
of operators. All
outcome measures
reported.
Anitua et al. (2009) Dental implantsurgery
Amoxicillin 2g
preoperatively vs.
moxifloxacin 400 mg vs
clindamycin 600 mg
preoperatively vs
placebo
n = 105
Randomised,
multicentre,
double blind,
parallel, placebo
controlled
Postoperative
infections,
microbiological
analysis, adverse events
and implant failures.
Spain
Six post op infections
occurred and 2 implant
failures in each group. No
statistically significant
differences observed
between groups.
No patient drop outs.
Results may be
applicable to bone
types II & 3 only. No
other bone types
investigated.
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3.3. Implant Failure
Data was pooled using REVMAN 5.0 software (Appendix A). Overall, results show more than
twice the number of implant failures occurred in the placebo/no antibiotic group (4.8%) vs. antibiotic
group (1.8%); RR 0.43; 95% CI 0.16 to 1.14.
The forest plot is a graphical representation of effect estimates and confidence intervals for each
study using risk ratio (RR) and % weight as representation of event data. The blue box corresponds
to the risk ratio point estimate and the % weight of each study is represented by the size of the box.
Esposito et al. (2010) contributed the largest weighting (66%) for this particular outcome measure
and is therefore represented by the largest blue box. Each horizontal line passing through a blue box
depicts the 95% confidence interval (CI) range of intervention effects compatible with the study’s
result. This indicates whether each effect was individually statistically significant for that particular
study. The line of no effect is seen passing vertically through 1 (when using RR). The overall combined
data (overall effect estimate) is graphically represented on the forest plot by a black diamond box.
This provides a meta-analytic summary of all data for an outcome to provide the best possible estimate
of the effect of the intervention with confidence interval. The height of the black box represents the RR
(0.64), whilst the width represents the 95% CI (0.43; 0.16–1.14)
A risk ratio describes the multiplication of the risk which occurs due to experimental (antibiotic)
intervention. Results show a risk ratio of 0.43 (95% CI 0.16–1.14), implying that antibiotics probably
reduce the risk of implant failure by 57% (100 × (1 − RR)%) [35] based on these 711 patients under
normal conditions. This is also known as the relative risk reduction. However according to the results
of this review, prophylactic antibiotics were not statistically beneficial in those undergoing implant
surgeries since p value (p = 0.09) for overall effect is greater than 0.05. This can also be seen in the forest
plot (Figure 2) as each individual 95% CI passes through the line of no effect and the overall effect
black box is in contact with the line of no effect. According to the Cochrane guidelines for systematic
reviews of interventions 5.1.0, small study effects are difficult to identify with less than 10 studies and
so a funnel plot may not be useful in this instance.
Medicina 2018, 54, x 14 of 27 
 
3.3. Implant Failure 
Data was pooled using REVMAN 5.0 software (Appendix A). Overall, results show more than 
twice the number of implant failures occurred in the placebo/no antibiotic group (4.8%) vs. antibiotic 
group (1.8%); RR 0.43; 95% CI 0.16 to 1.14. 
The forest plot is a graphical representation of effect estimates and confidence intervals for each 
study using risk ratio (RR) and % weight as representation of event data. The blue box corresponds 
to the risk ratio point estimate and the % weight of each study is represented by the size of the box. 
Esposito et al. (2010) contributed the largest weighting (66%) for this particular outcome measure and 
is therefore represented by the largest blue box. Each horizontal line passing through a blue box 
depicts the 95% confidence interval (CI) range of intervention effects compatible with the study’s 
result. This indicates whether each effect was individually statistically ignificant for that particular 
study. The lin  of no eff ct is seen p ssing vertically through 1 (when using RR). The overall 
combine  d ta (overall effect estimate) is gr phically represented on th  forest plot by a black 
diamond box. This provides a meta-analytic summary of all data for an outcome t  provide the best 
possible estimate of the effect of the intervention with confidence interval. The height of the black box 
represents the RR (0.64), whilst the width represents the 95% CI (0.43; 0.16–1.14) 
A risk ratio describes the multiplication of the risk which occurs due to experimental (antibiotic) 
intervention. Results show a risk ratio of 0.43 (95% CI 0.16–1.14), implying that antibiotics probably 
reduce the risk of implant failure by 57% (100 × (1 − RR)%) [35] based on these 711 patients under 
normal conditions. This is also known as the relative risk reduction. However according to the results 
of this review, prophylactic antibiotics were not statistically beneficial in those undergoing implant 
surgeries since p value (p = 0.09) for overall effect is greater than 0.05. This can also be seen in the 
forest plot (Figure 2) as each individual 95% CI passes through the line of no effect and the overall 
effect black box is in contact with the line of no effect. According to the Cochrane guidelines for 
systematic reviews of interventions 5.1.0, small study effects are difficult to identify with less than 10 
studies and so a funnel plot may not be useful in this instance. 
 
Figure 2. A forest plot of comparison showing antibiotics vs. placebo/no antibiotics for implant 
failure. 
3.4. Adverse Events 
Adverse events were reported in only 2 out of 7 studies [32,34], of which only one study saw 
adverse events occur in the placebo/ no antibiotic group. Overall results (Figure 3) show that there is 
no statistical significance for adverse events (P = 0.30). The risk ratio of 1.84 (95% CI 0.59 to 5.77) 
implies (based on these results) that a patient is 1.84 times more likely to experience adverse events 
with treatment than adverse events without treatment. Alternatively, this can also be expressed as: 
100 × (RR − 1)% = 100 × (1.84 − 1) = 100 × (0.84) = 84%. Treatment increases the risk of adverse events 
by 84% in the antibiotic group. Calculating the numbers needed to treat (NNT) helps understand the 
impact of an intervention on an outcome. Based on the results of this review, evidence suggests that 
approximately 33 patients undergoing dental implant surgery need to receive antibiotics in order to 
prevent one implant failure from occurring (Figure 2 and Table 7). 
Figure 2. A forest plot of comparison showing antibiotics vs. placebo/no antibiotics for implant failure.
3.4. Adverse Events
Adverse events were reported in only 2 out of 7 studies [32,34], of which only one study saw
adverse e nts occur in the placebo/ n antibio ic group. Overall results (Figure 3) show that there
is no statistical significance for adverse events (p = 0.30). The risk ratio of 1.84 (95% CI 0.59 to 5.77)
implies (based on these results) that a patient is 1.84 times more likely to experience adverse events
with treatment than adverse events without treatment. Alternatively, this can also be expressed
as: 100 × (RR − 1)% = 100 × (1.84 − 1) = 100 × (0.84) = 84%. Treatment increases the risk of adverse
events by 84% in the antibiotic group. Calculating the numbers needed to treat (NNT) helps understand
the impact of an intervention on an outcome. Based on the results of this review, evidence suggests
that approximately 33 patients undergoing dental implant surgery need to receive antibiotics in order
to prevent one implant failure from occurring (Figure 2 and Table 7).
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Table 7. Number need to treat calculation.
Numbers Need to Treat (NNT)
Control group event rate (CER): proportion of outcomes that occur in control group.
Experimental group event rate (EER): proportion of outcomes that occur in the experimental group.
Absolute risk r duction (ARR) = CER − EER
Number eeded to treat (NNT) = 1/ARR
To prevent implant failure using prophylactic antibiotics:
CER = 16/332 = 0.048
EER = 7/379 = 0.018
Absolute risk reduction (ARR) = 0.048 − 0.018 = 0.030
NNT = 1/0.030 = 33.333
Approximately 33 patients undergoing dental implant surgery need to receive antibiotics in order to prevent
one implant failure from occurring (NNT)
No statistically sig ificant evidenc was fou d for post-operativ complications (Figure 4)
following dental implant placement (p = 0.47, RR: 0.74; 95% CI 0.34–1.65). A risk ratio of 0.74 (95% CI
0.34–1.65), implies that antibiotics probably reduce the risk of post-operative complications by 26%
(100 × (1 − RR)%).
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4. Discussion
4.1. Dental Extraction
In general, few statistically si ific t res lts ere seen across all included extraction studies for
all the listed outcomes. Two out of the four extrac ion studies were rega ded as low risk of bias [35–37],
both of which reported that preoperative antibio cs were associat d with reduced prevalence of
bact r emia levels and reduced risk of infe tion. Amoxicillin given preoperatively showed higher
efficacy than moxifloxacin and clindamycin (p < 0.001 and p < 0.05 respectively). Amoxicillin was
more favourable in reducing serum b cteraemia le ls in c mparison to placebo (p < 0.0001) [33].
Lacasa et al. (2007) found a statistic lly significant linear correlation betwee an increase in length of
procedure and incidence of infection (p < 0.027). Dental extraction performed with ostectomy (bone
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removal) takes longer to perform and so this was evident in all arms of the trial vs. rate of infection
without ostectomy.
Adverse events were reported in only two studies [35,37], of which only one study saw events
occur in the placebo/ no antibiotic group. Only two minor adverse events had been reported in
antibiotic groups for included studies (diarrhoea and itching). This indicates that these antibiotic
regimens seem to have been well tolerated but due to the small sample size of patients included in this
review it is not possible to assess the occurrence of other rare adverse events associated with antibiotic
use such as anaphylactic shock.
There is a minor trend showing adverse events occurring more so in the antibiotic group across
the only two trials which reported any adverse events (2.43% in antibiotic group vs. 0.71% in placebo
group). However, results of the present review show there is no statistical significant results for
adverse events between groups (p = 0.30). Based on these results, a risk ratio of 1.84 (95% CI 0.59–5.77)
implies a patient is 84% more likely to experience adverse events with treatment than adverse events
without treatment.
Overall, 2 out of 3 extraction studies [12,35] which report postoperative inflammatory
complications as an outcome measure do not support the use of prophylactic antibiotics after third
molar extraction (n = 237). Lacasa et al. (2006) found pre-emptive antibiotics are more beneficial than
prophylactic antibiotics for complex extractive surgery requiring ostectomy (p = 0.006). The authors
recommend single dose prophylaxis in simpler extractive procedures where ostectomy is not performed
to reduce postoperative complications. Two of the lead authors of this phase III clinical study are
employees of the drug company funding the phase III trial.
4.2. Dental Implants
Using three extraction studies (n = 711), the present study has found no statistically significant
evidence to support the use of routine prophylactic antibiotics in reducing the risk of implant failure
(p = 0.09, RR 0.43; 95% CI 0.16 to 1.14) and post-operative complications (p = 0.47, RR: 0.74; 95% CI
0.34–1.65). The only trial which used 3 various prophylactic antibiotic durations [14] failed to reveal
conclusive evidence as not a single outcome event occurred in any arm of the trial (postoperative
infection, prosthesis/implant failure, adverse events).
A risk ratio of 0.43 for implant failure implies that prophylactic antibiotics probably reduce the
risk of implant failure by 57% based on these 711 patients under normal conditions. Antibiotics
probably reduce the risk of post-operative complications following implant placement by 26% (RR:
0.74; 95% CI 0.34–1.65). Approximately 33 patients undergoing dental implant surgery need to receive
antibiotics in order to prevent one implant failure from occurring (NNT, Table 7). This will cost £120.00
for 33 patients to receive a 2 g amoxicillin prophylactic dose [22] in order to prevent one implant failure.
Although this may seem financially feasible, clinicians must carefully consider the increase in rate of
antibiotic resistance and the chance of allergic/toxic reactions occurring before deciding to treat 33
patients in order to prevent one implant failure from occurring.
4.3. Other Views
A systematic review conducted by Esposito et al. (2013) assessed the beneficial or harmful effects
of systemic prophylactic antibiotics at dental implant placement vs. placebo. Six randomised controlled
clinical trials (RCTs) with a follow-up of at least three months were analysed which compared the
administration of various prophylactic antibiotic regimens vs. placebo to patients undergoing dental
implant placement. The authors conclude their evidence suggests that, in general, antibiotics are
beneficial for reducing the failure of dental implants placed in ordinary conditions vs. placebo
(p = 0.002, OR 0.33; 95% CI 0.19–1.00). No statistically significant differences were seen between groups
regarding postoperative complications (p = 0.28, RR 0.60: 95% CI 0.36–1.35) or adverse events (p = 1.0,
RR 1.0; 95% CI 0.006–15.85). The authors remain unsure whether postoperative antibiotics at dental
implant are beneficial, and which antibiotic would be the most effective.
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Schwartz & Larson (2007) conducted a detailed literature review to assess ‘antibiotic prophylaxis
and postoperative complications following tooth extraction and implant placement’. Eight randomised
clinical trials, one retrospective study and four additional randomised interventions were studied.
In general sample sizes were small and provided insufficient statistical power to avoid type II, or false
negative errors. The work emphasises how methodological differences in many of the dental clinical
trials pose a problem regarding quality of evidence. The study concludes that there is a lack of
evidence regarding the use of prophylactic antibiotics in general dentistry, including tooth extraction
and implant placement [10].
A recent Cochrane systematic review conducted by Lodi et al. (2012) investigated the benefits
of antibiotic prophylaxis in patients undergoing tooth extraction(s) for any indication. The authors
found statistically significant evidence for a reduction in dry socket, pain, fever and trismus (p < 0.05).
An increase in mild and transient adverse effects was observed in antibiotic groups vs. placebo. They
conclude there is evidence that antibiotic prophylaxis reduces the risk of dry socket pain and infection
following third molar extractive surgery. The main limitation of the review was almost half of the
assessed trials were conducted before 1992 (6 of which were conducted in the 1980’s) and many of
which used selective reporting, incomplete outcome data and wide variations in methodological
approaches. All studies included were either high risk of bias or had an unclear risk of bias, and
therefore this may question the reliability of results [38,39].
Martin et al. (2005) assessed the appropriateness of antibiotic prophylaxis for third molar
extractive surgery. The body of evidence examined showed that antibiotics may provide certain
benefits in certain circumstances and little or no benefit in other circumstances. For example, it was
found prophylactic antibiotics may be beneficial in extractive surgery requiring bone removal. Despite
this, the authors believe the body of evidence questions the benefit of routine prophylactic antimicrobial
therapy which does not appear to overcome risk of undesirable outcomes after dental extraction of
third molars [9].
4.4. Limitations
One of the main limitations of the present review is that only seven studies were identified and
available for review. Although the clinical extraction studies used in this review were conducted in
various countries worldwide, many of the patients were young healthy patients in their early twenties
and so the results of the review were more applicable to healthy young adults undergoing surgical
tooth extraction. In contrast, older participants were recruited across all included implant studies
(varying between 42–52 years). No trials were identified which included young children, elderly
patients or immune compromised patients requiring dental extractions, therefore the results of this
review may not be applicable to this group although they would be expected benefit more from
prophylactic antibiotics due to increased risk of infection. Indeed, the NNT for outcomes would be
likely to decrease if this group of patients were to be included, however it may not be possible or
ethical to conduct clinical studies using this group of patients. Extraction studies identified involved
patients being treated by oral surgery specialists by referral and so again, it is unclear whether these
results are relatable to general dental practice. No clinical extraction studies were found evaluating the
use of prophylactic antibiotics for patients with periodontal complications or severe caries as these are
the most common indications for dental extractive surgery of third molars.
4.5. Implications for Dentists
A clinician’s awareness about correct antibiotic choice is key to reducing ‘blind prescribing’,
a factor which has contributed to the increase in antibiotic resistant microorganisms. Changes required
in antibiotic prescribing habits presents its own set of problems as described by Soheilipour et al.
(2011) whereby a qualitative study regarding the views of healthcare professionals on NICE guidelines
revealed that prescribers experienced difficulty in explaining to their patients the change in clinical
practice necessitated by adherence to the NICE guidance [40]. Concerns were also raised about
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the legal position of a clinician who did not follow the guidance. Further monitoring of antibiotic
prescriptions among dentists is needed in order to effectively audit this controversial therapy. It is
also recommended for continuing education of practitioners regarding the growing public health risks
related to antibiotic prescriptions.
4.6. Implications for Further Work
There are varying opinions regarding the prophylactic use of antibiotics in dentistry [8–10].
More large scale randomised, double blind clinical studies need to be conducted. There is also a lack
of clinical studies which have evaluated and defined the most appropriate and effective antibiotic
regimen for dental procedures and so further work is recommended based on these proposals.
5. Conclusions
No statistically significant evidence was found to support the routine use of prophylactic antibiotics
in reducing the risk of implant failure or post-operative complications under normal conditions.
Approximately 33 patients undergoing dental implant surgery need to receive antibiotics in order to
prevent one implant failure from occurring. Prophylactic antibiotics probably reduce the risk of implant
failure by 57% based on 711 patients under normal conditions. There is also little conclusive evidence
favouring the routine use of prophylactic antibiotics for third molar extractive surgery requiring bone
removal in healthy young adults.
No trials were identified with the group of patients that would most likely benefit from the use of
prophylactic antibiotics; elderly, young and immunocompromised patients. The results of the present
study may therefore not be applicable to this group of patients. No trials were identified for the most
common indications for dental extraction; dental caries or periodontal disease.
Much remains to be achieved in dental research including further large scale randomised,
double-blind clinical studies using patients with infective complications such as infective endocarditis
or immuno-compromised patients for various dental procedures.
Based on the articles analysed in this review it is recommended that clinicians carefully consider
the appropriate use of antibiotics in dental implants and extraction procedures even if it is financially
feasible due to risk of allergic/toxic reactions and the development of antibiotic resistance. Further
monitoring of antibiotic prescribing in dentistry is required in addition to continuing education for
dentists concerning the public health risks associated with antibiotic misuse.
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Appendix A. Outcome Measures and Statistical Analysis Using REVMAN 5.0 Software
Data was pooled using REVMAN 5.0 software. The relative risk (RR) with 95% confidence
intervals (CIs) for dichotomous data (data with two mutually exclusive groups, i.e., occurrence of
implant failure or not, presence or absence of adverse events and presence and absence of postoperative
complications was calculated for each study to quantitatively measure the probability of an event
occurring. Where possible, based on the reviewed study design, the numbers needed to treat (NNT)
were calculated to measure the number of patients who need to be treated to prevent one additional
adverse outcome.
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Appendix B. CASP Forms Checklists Templates Were Used from CASP International
Network (2013)
CASP Analysis of Dios et al. (2006)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The authors evaluated the efficacy of Amoxicillin 2 g preoperatively vs moxifloxacin 400 mg vs. clindamycin 600
mg preoperatively vs. placebo (5-day treatment) for the prevention of bacteraemia following dental extraction.
2. Was the assignment of patients to treatments randomised?
Yes. Randomisation was based on a single sequence of random assignments using a computer generated
randomisation list.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
Yes. All 221 patients had been accounted for in results and conclusion of the study
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
Study is described as ‘double-blind’.
5. Were the groups similar at the start of the trial?
Size and composition of all three groups were similar
Amoxicillin 2 g preoperatively (n = 56): 34 (M)/22 (F), mean age = 23.8 years
Moxifloxacin 400 mg preoperatively (n = 58): 29 (M)/29 (F), mean age = 22.4 years
Clindamycin 600 mg preoperatively (n = 54): 34 (M)/20 (F), mean age = 24 years
Placebo (n = 53): 29 (M)/24 (F), mean age = 26.1 years
The range of total extractions per group ranged from 53–58.
6. Aside from the experimental intervention were the groups treated equally?
All patients were subjected to the same inclusion/ exclusion criteria and all extractions were conducted in the
Santiago de Compostela University Hospital (Spain) under general anaesthesia.
Section (B) What are the results?
7. How large was the treatment effect?
The presence of bacteraemia following dental extraction was measured as the outcome of interest. Streptococcus
spp. were the most commonly identified bacteria in all groups ranging from 44 to 68% with the lowest percentage
being detected from the amoxicillin group (p < 0.0001).
Amoxicillin and moxifloxacin prophylaxis showed high efficacies (p < 0.001 and p < 0.05 respectively) in reducing
prevalence and duration or bacteraemia. Clindamycin prophylaxis was seen to be non-effective (p < 0.9).
8. How precise was the estimate of the treatment effect?
No confidence intervals are provided in the study, however p-values have been provided.
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be applicable to a general population. Patients did not comprise of the elderly, young children,
immunocompromised patients or those at risk of IE. Patient mean age was in mid-20’s. A larger sample size
would be required. Furthermore, the procedures were carried out in a hospital setting rather than a dental practice.
General anaesthesia was used, but local anaesthetic is more commonly for tooth extraction (depending on
complexity of extraction).
10. Were all clinically important outcomes considered?
No. Adverse events were not considered as an outcome measure. Signs of infection were not considered as
outcome measures.
11. Are the benefits worth the harms and costs?
The study shows that amoxicillin and moxifloxacin prophylaxis showed high efficacies (p < 0.001 and p < 0.05
respectively) in reducing prevalence and duration or bacteraemia following dental extraction, and therefore
beneficial. This of course in turn would be highly likely to reduce postoperative complications.
Commonly prescribed antibiotics used in dentistry are relatively cheap in the UK, however the type of antibiotic
prescribed to patients should be strongly considered by prescribers as well as considering the genuine need for
that particular patient, for example, in general, the elderly, immunocompromised and younger patients would
seem more likely to benefit from prophylactic antibiotics as opposed to blind prescribing for each and every
individual undergoing tooth extraction.
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CASP Analysis of Sekhar et al. (2001)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The authors attempted to test the efficacy of two dosing regimens of prophylactic antibiotics for the removal of
impacted third molars. The Intervention used was metronidazole 1 g orally 1hr preoperatively vs.
metronidazole 400 mg orally 4 times daily for 5 days vs. placebo.
2. Was the assignment of patients to treatments randomised?
Method of sequence generation was not fully described; however, study claims to have used randomisation in
sealed envelopes (allocation).
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
151 patients were randomised at the beginning of the study and 125 were accounted for at its conclusion. The
results of those who did not complete the study were also provided and statistically analysed, finding no
significant differences between groups.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
The outcome assessor was blinded to allocated treatment. Study is described as double-blind (dosing schedule
is different in each group).
5. Were the groups similar at the start of the trial?
Size of all four groups saw slight variation in number of participants shown below. The composition of
each group saw slight variations:
Metronidazole 1 g orally 1 h preoperatively (n = 44): 25 (M)/19 (F), mean age = 28 years
Metronidazole 400 mg orally 4 times daily for 5 days (n = 47): 30 (M)/17 (F), mean age = 29 years
Placebo (n = 34): 15 (M)/19 (F), mean age = 26 years
The range of total extractions per group ranged from 99–103.
6. Aside from the experimental intervention were the groups treated equally?
All patients were subjected to the same inclusion/exclusion criteria and all extractions were conducted in one
treatment centre in India. It is worthy to note however that surgeons performing the extraction were of
different skill levels i.e., some were consultants, post-graduate trainees or house officers.
Section (B) What are the results?
7. How large was the treatment effect?
No significant differences in outcome between three groups (p = 0.09). The only significant difference seen was
the degree of swelling in the 5 day group (p = 0.03).
Overall, antibiotic prophylaxis does not seem to reduce morbidity after third molar extraction surgery.
8. How precise was the estimate of the treatment effect?
No confidence intervals are provided. Only standard deviation figures were provided for individual results.
Overall the study showed no statistically significant results to recommend prophylactic antibiotics for the
extraction of third molars.
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be applicable to a general population. Patients did not comprise of the elderly, young children,
immunocompromised patients or those at risk of IE. A larger sample size would be required. Furthermore,
surgeons were of different skill levels and the procedure itself was not carried out in a dental practice were
most extractions are carried out in the UK.
10. Were all clinically important outcomes considered?
No. Adverse events were not considered as an outcome measure.
11. Are the benefits worth the harms and costs?
Results were not statistically significant (p > 0.05), and so there is not enough evidence to support the use of
antibiotics in this case. Metronidazole is relatively cheap in the UK but the risk of other complications such as
microbial resistance may outweigh the benefit if it is to be routinely prescribed for a procedure which in this
case has failed to show statistically significant results.
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CASP Analysis of Esposito et al. (2010)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
To evaluate the efficacy of antibiotic prophylaxis for dental implant placement. The intervention used was
amoxicillin 2 g pre-op vs. amoxicillin 2 g daily pre & post-op (7 days) vs. amoxicillin 2 g post-op (7 days) vs.
placebo. Outcomes considered were implant failure, postoperative complications assessed post-op at weeks 1, 2, 4
and 8, adverse events.
2. Was the assignment of patients to treatments randomised?
Yes.
Computer generated restricted randomisation lists (13 in total) were formed using equal groups of participants.
Randomised codes were enclosed in sequentially numbered, identical, opaque, sealed envelopes. Treatment
allocation was concealed to investigators in charge of enrolling and treating the patients.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
Two exclusions were made from the control group (antibiotic group) and one from the non-antibiotic group with
reasons provided.
Patients were analysed in groups they were randomised to.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
Yes.
Patients and operators/outcome assessors were blinded to intervention. The statistician was also kept blind when
performing all analyses for this study
5. Were the groups similar at the start of the trial?
Yes. Similar
Amoxicillin group (n = 52): 114 (M)/138 (F). Mean age 49.1
Placebo group (n = 254): 112 (M)/132 (F). Mean age 47.9
6. Aside from the experimental intervention were the groups treated equally?
Yes. Patients were treated in 10 private Italian practices. The number of implant placements for each group were
similar (498; antibiotic group vs. 483; control group).
Section (B) What are the results?
7. How large was the treatment effect?
No statistically significant differences were seen to be observed. However trends to favour the antibiotic group.
The study furthermore concludes immediate post-extractive implants were more likely to fail.
Implant failure: 7 in antibiotic group vs. 13 placebo group
Prosthesis failure: 4 failures in antibiotic group vs. 10 placebo group
Adverse events: none reported.
Post-operative complications: 11 in antibiotic group vs. 13 in placebo group
8. How precise was the estimate of the treatment effect?
Confidence interval not provided. p = 0.083 for overall implant losses (not statistically significant).
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Cannot tell.
Implant placement is not limited to sex/age. Most patients in this trial were >40 years. Results may not be
generalisable to a whole general population. Patients did not comprise of the elderly, young children,
immunocompromised patients or those at risk of IE. A larger sample size would be required.
10. Were all clinically important outcomes considered?
Yes.
All outcomes considered and reported, however confidence intervals should have been provided. A different
dosing regimen group could also have been used.
11. Are the benefits worth the harms and costs?
Can’t tell.
Trends are clearly in favour of antibiotics as more implant, prosthesis failures and post-operative complications
were seen in the placebo group vs. antibiotic group. Despite this the results were not statistically significant (p =
0.083). No adverse events were reported but this may be due to the small sample size of the study. Amoxicillin is
relatively cheap in the UK but the risk of other complications such as microbial resistance may outweigh the
benefit if it is to be routinely prescribed for a procedure which fails to show statistically significant results.
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CASP Analysis of Kaczmarzyk et al. (2007)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The authors attempted to evaluate the efficacy of two antibiotic regimens (single dose clindamycin and multidose
clindamycin (5 days) for the reduction of inflammatory complications in patients undergoing third molar surgery
with bone removal (extraction).
Outcomes of interest were trismus, facial swelling, body temperature, pain, submandibular lynphadenopathy and
alveolar osteitis.
2. Was the assignment of patients to treatments randomised?
A random number table was used for to determine group assignment for each patient in advance. Furthermore,
allocation concealment involved opaque and sequentially numbered envelopes.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
Nine out of 100 patients did not check in for follow up. Three had been disqualified due to various described
complications and two had resigned during the trail without stating any reasons. Therefore 86 patients in total were
analysed statistically at the end of the trial.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
Patients, clinicians and statisticians were all blinded.
5. Were the groups similar at the start of the trial?
Sizes of all three groups were similar (n = 27–31) The composition of each group was very similar except one group
composed of a higher female population.
Clindamycin 600 mg preoperatively then 300 mg placebo for 5 days: 8 (M)/23 (F), mean age = 23.4 years
Clindamycin 600 mg preoperatively then 300 mg placebo for 5 days post-op: 9 (M)/19 (F), mean age = 23.5 years
placebo: 6 (M)/21 (F), mean age = 24.6 years
Total extractions between groups ranged from 27–31.
6. Aside from the experimental intervention were the groups treated equally?
Yes.
All groups were treated at one treatment center in Poland and subject to the same inclusion/exclusion criteria.
Section (B) What are the results?
7. How large was the treatment effect?
There was no statistically significant differences observed between groups for postoperative alveolar osteitis, pain
scores, postoperative trismus and facial swelling (p > 0.05).
Regarding a change in body temperature, a statistically significant difference between groups was recorded (p = 0.03).
Despite this one statistically significant result for this study, the authors conclude that there is not enough evidence to
suggest that clindamycin used prophylactically by itself or with subsequent 5-day therapy fails to demonstrate
significant efficacy for prevention of inflammatory complications after third molar surgery.
8. How precise was the estimate of the treatment effect?
The X2 test was used to evaluate trismus, facial swelling, lymphadenopathy and alveolar osteitis using an odds ratio
with a confidence interval of 95%. The Krukal-Wallis rank test was used to analyse surgery duration, analgesic intake,
body temperature and level of pain experienced.
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be applied to a whole general population. Patients were not treated in a general dental surgery, where
most extractions take place. Patients did not comprise of the elderly, young children, immunocompromised patients
or those at risk of IE. The mean age of patients across all three groups was in the mid 20’s, and so they may be more
applicable to younger adults, however even then, larger sample sizes than this study would also require to represent a
typical population of patients.
10. Were all clinically important outcomes considered?
No. All-important outcomes were considered except adverse events were not reported.
11. Are the benefits worth the harms and costs?
Results described above are not statistically significant. In the case of this study, adverse events were not reported.
With regards to cost, clindamycin is relatively cheap in the UK but the risk of other complications such as microbial
resistance may outweigh the benefit if it is to be routinely prescribed for an extraction procedure which is
uncomplicated and of short duration.
Overall, the study shows there is little benefit from taking prophylactic antibiotics for the reduction in inflammatory
complications following third molar surgery.
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CASP Analysis of Lacasa et al. (2007)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The authors attempted to evaluate the efficacy of two sustained release antibiotic regimens for the reduction of
infection after third molar surgery (extraction): Pre-op amoxicillin/clavulanate 2000/125 mg vs post-op
amoxicillin/clavulanate 2000/125 mg vs. placebo (5 day treatment). Outcomes of interest were Infection (purulent
discharge in surgical site, pain, local abscess, increased heat, pyrexia, trismus, dental osteitis. All evaluated on days 1,
3, 7 post-op.
2. Was the assignment of patients to treatments randomised?
Allocation concealment is not mentioned and therefore an unclear risk. Also random sequence generation is
mentioned as randomised, however the method of how it was generated has not been provided.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
Every patient was accounted for at conclusion.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
All were blinded.
5. Were the groups similar at the start of the trial?
Size of all four groups were identical (n = 75 for each group). The composition of each group was very similar except
one group composed of a higher female population.
Pre-op amoxicillin/clavulanate 2000/125 mg: 33 (M)/42 (F), mean age = 29.7 years
post-op amoxicillin/clavulanate 2000/125 mg: 37 (M)/48 (F), mean age = 52 years
placebo: 26 (M)/49 (F), mean age = 28.2 years
Each group had a total of 75 extractions (1 extraction per patient)
6. Aside from the experimental intervention were the groups treated equally?
Yes.
All groups were treated at one treatment centre and subject to the same inclusion/exclusion criteria.
Section (B) What are the results?
7. How large was the treatment effect?
Higher rate of infection was seen in placebo group (16%) vs. single dose prophylaxis (5.3%) vs. 5 day pre-emptive
therapy (2.7%) (p = 0.006) meaning results were statistically significant. A significant result was seen in the correlation
between the longer duration of surgery and rate of infection (p = 0.011) (although initially this was not an outcome of
interest). Pre-emptive and pre-operative antibiotics vs. placebo saw a greater reduction of postoperative pain on day 3
(p = 0.0001)
Overall pre-emptive therapy is better suited for more complex procedures (extraction including bone removal).
Prophylaxis is more beneficial in simpler procedures.
8. How precise was the estimate of the treatment effect?
Details on CI were not included for results of the study; however they were provided for the reasoning behind why 75
patients were required in each study group in order to achieve a sufficient sample size (based on a previous pilot
study with smaller samples sizes)
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be generalisable to a whole general population. Patients were not treated in a general dental surgery,
where most extractions take place. Patients did not comprise of the elderly, young children, immunocompromised
patients or those at risk of IE. The mean age of patients across all three groups was in the late 20’s. A larger sample
size would also be required.
10. Were all clinically important outcomes considered?
Yes, however the CI for each outcome considered was not provided (although p values were).
11. Are the benefits worth the harms and costs?
Results described above are statistically significant. Generally adverse events were seen more frequently in the
pre-emptive antibiotic group and with greater effect compared to prophylaxis and placebo groups. Therefore the
choice of antibiotic regimen should be carefully considered when judging the difficulty of extraction and the benefits
of administration to each individual patient.
With regards to cost, amoxicillin is relatively cheap in the UK but the risk of other complications such as microbial
resistance may outweigh the benefit if it is to be routinely prescribed for an extraction procedure which is
uncomplicated and of short duration.
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CASP Analysis of Anitua et al. (2010)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The study compared the efficacyand safety of oral amoxicillin 2 g with identical placebo tablets taken prophylacticaly
(1 h before implant placement) for single dental implants in bone type 2 & 3. Outcomes considered. Outcomes of
interest included implant failure, postoperative complications assessed post-op at weeks 1, 2, 4 & 8, adverse events
and microbiological evaluation.
2. Was the assignment of patients to treatments randomised?
How was this carried out?
Was the allocation sequence concealed from researchers and patients?
Yes.
Researchers had a concealed envelope for each patient to establish randomly assigned treatment if necessary
(envelope opened at end of study). If a side effect was observed, then the clinician was allowed to open the envelope
before the end of the study.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
A 52 patients were enrolled into the antibiotic group and 53 patients were enrolled into the placebo group for which
results for all patients were given at the end of the study.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
Yes. Researchers and patients were blinded to the received treatment group.
5. Were the groups similar at the start of the trial?
Size of both groups were almost identical (antibiotic group n = 52 & non antibiotic group n = 53. The composition of
each group was also similar except the male to female ratio in one of the groups:
Amoxicillin 2 g 1h pre-op: 15 (M)/37 (F), mean age = 49 years.
Placebo (identical tablets) 2 g 1hr pre-op: 20 (M)/33 (F), mean age 53.
6. Aside from the experimental intervention were the groups treated equally?
Yes. This study only included people requiring a single implant into bone of medium quality. Only one implant was
provided to each patient in each group. Patients were also treated in same country (8 Spanish dental practices)
Section (B) What are the results?
7. How large was the treatment effect?
Outcome measures included:
Implant failures: 2 failures occurred in each group
Adverse events: none reported
Postoperative infections: 6 in each group. The probability of not having and infection was 88.8% in the non-antibiotic
group vs. 88.8% in the antibiotic group. No statistical differences reported (p = 0.0960)
Characteristics of saprophytic flora: no statistically significant results observed, the amoxicillin did not alter or modify
the nature of the saprophytic flora (p = 0.362)
Overall the study concludes that there is no statistically significant data to suggest antibiotic prophylaxis when
placing single implants in patients with bone types 2 & 3.
8. How precise was the estimate of the treatment effect?
The type of treatment applied did not significantly affect the probability of occurrence of infections (OR 0.97—CI 95%
0.29–3.2)
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be generalisable to a whole general population. Patients did not comprise of the elderly, young
children, immunocompromised patients or those at risk of IE. A larger sample size would be required. Furthermore,
only patients with bone types 2 & 3 were used and so results are more applicable to these patients.
10. Were all clinically important outcomes considered?
Yes.
All outcomes considered and reported. A different dosing regimen group could also have been tested.
11. Are the benefits worth the harms and costs?
Not in this case. Insufficient statistically significant evidence.
Results were not statistically significant (p > 0.05).
Amoxicillin is relatively cheap in the UK but the risk of other complications such as microbial resistance may outweigh
the benefit if it is to be routinely prescribed for a procedure which fails to show statistically significant results.
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CASP Analysis of Caiazzo et al. (2010)
Section (A) Are the results of the review valid?
Screening Questions
1. Did the trial address a clearly focused issue?
Yes.
The authors attempted to determine the minimum effective regimen of antibiotic prophylaxis (amoxicillin) for
dental implant surgery. The intervention used was amoxicillin 2 g pre-op vs. amoxicillin 2 g daily pre-&
post-op (7days) vs. amoxicillin 2 g post-op (7days) vs. placebo.
2. Was the assignment of patients to treatments randomised?
No information regarding the allocation concealment procedure was provided. A computer generated
randomisation list was produced to allocate patients into one of four groups.
3. Were all of the patients who entered the trial properly accounted for at its conclusion?
All adults were treated in two private Italian dental practices. Results for all 100 patients (4 groups of 25) who
entered the trial were provided at the end of the trial.
Detailed questions
4. Were patients, health workers and study personnel ‘blind’ to treatment?
Operators were not blinded as they were recording the outcome measures.
5. Were the groups similar at the start of the trial?
Size of all four groups were identical (n = 25 for each group). The composition of each group saw slight
variations:
Amoxicillin 2 g 1 h pre-op (n = 25): 13 (M)/12 (F), mean age = 52 years
Amoxicillin 2 g 1 h pre-op + amoxicillin 2 g daily for 7 days post-op (n = 25): 12 (M)/13 (F), mean age = 45 years
Amoxicillin 2 g daily post-op for 7 days (n = 25): 7 (M)/18 (F), mean age = 42 years
No antibiotic (n = 25): 10 (M)/15 (F), mean age = 43 years
The range of total implants per group ranged from 29–48.
6. Aside from the experimental intervention were the groups treated equally?
Yes.
All groups were treated at two Italian private dental clinics subject to the same inclusion/exclusion criteria.
Section (B) What are the results?
7. How large was the treatment effect?
Outcomes of interest included:
Implant failure: 2 implant failures in no antibiotic group
No postoperative complications observed post-op at weeks 1, 2, 4 and 8
Adverse events: none reported
8. How precise was the estimate of the treatment effect?
Power analysis showed only 15% with confidence at 99% and 35% at 95% CI. However further calculations
revealed that in order to achieve a power of 75% with 99% confidence, 133 samples are required in each group;
a much larger quantity than the current 25 per group is required to further provide strong statistical evidence
of the absence of treatment effect.
Section (C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
Results may not be generalisable to a whole general population. Patients did not comprise of the elderly,
young children, immunocompromised patients or those at risk of IE. A larger sample size would be required.
10. Were all clinically important outcomes considered?
Yes.
All outcomes considered and reported. A different dosing regimen group could also have been tested.
11. Are the benefits worth the harms and costs?
Not in this case. Insufficient statistically significant evidence (p > 0.05).
No adverse events were reported but this may be due to the small sample size of the study. Amoxicillin is
relatively cheap in the UK but the risk of other complications such as microbial resistance may outweigh the
benefit if it is to be routinely prescribed for a procedure which fails to show statistically significant results.
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